Main Catalog

AMCP Web Site

Main Catalog

Found 88

Sort by

Member Free

Non-Member $30.00

2019-2020 Pharmaceutical Marketplace Trends

Not Accredited for CPE: This online program will provide an up-to-the-minute analysis of the pharmaceutical market and offer predictions about what lies ahead in the coming months as the health care industry manages the COVID-19 pandemic.

AMCP eLearning Days 2019-2020 Trends

Member Free

Non-Member $30.00

A Path Forward: Medicaid Accountable Care Organization Implementation

Contact Hours: 1.5. While a dozen states have implemented new Accountable Care Organization (ACO) Medicaid models, another 12 are in the planning phases.

Accountable Care Organization

Member Free

Non-Member $30.00

A State Medicaid’s Experience Implementing an Oversight Program for Behavioral Health Medications in Publicly Insured Youth

Contact Hours: 1.5. Utilization of behavioral health medications in the pediatric population has increased in recent years, a trend that has generated major concern given the limited supporting evidence.

Patient Care

Member Free

Non-Member $30.00

AMCP Federal and State Legislative/Regulatory Update Home Study 2020

Contact Hours: 1.0. In today’s world, healthcare legislation and regulation move at a staggering pace making it difficult for health professionals to keep up.

Law

Member Free

Non-Member $30.00

AMCP Headline Session: 2017–2018 Pharmaceutical Marketplace Trends

Not Accredited for CPE: Keeping abreast of industry trends and forecasts is vital to remaining competitive in the evolving managed care arena— especially because market predictions can shape the approach to managing the pharmacy benefit.

AMCP Headline Session 2018

Member Free

Non-Member $30.00

Best Practices in Combating Opioid Abuse, Misuse and Diversion: The Health Plan Perspective - Nexus 2017

Contact Hours: 1.5. The opioid epidemic in the United States continues to worsen. Roughly 91 Americans die each day from an opioid overdose.

Opioid

Member Free

Non-Member $30.00

Best Practices to Implementing Proactive Communications Between Manufacturers and Payers

Contact Hours: 1.25. The recent enactment of the 21st Century Cures Act, and specifically Section 3037 (Cures 3037), modernized provisions of the Food and Drug Administration Modernization Act of 1997, Section 114 (FDAMA 114).

Managed Care Regulation

Member Free

Non-Member $30.00

Biosimilars in the United States: Barriers, Solutions, Real-World Evidence, and the Experience of One Health System

Contact Hours: 1.5. As of July 2019, the U.S. Food and Drug Administration (FDA) had approved 25 biosimilar or follow-on biologic products.

Biosimilars

Member Free

Non-Member $30.00

Bracing for Impact: Preparing for the 2019 Specialty Drug Spend - Nexus 2017

Contact Hours: 1.5. The escalating cost of prescription drugs is an issue that continues to plague the U.S. health care system, accounting for 17% of the total health care spend in 2015.

Hospital/Health Systems

Member Free

Non-Member $30.00

Brand and Generic Drugs in Development

Contact Hours: 1.25. This session focuses on new and emerging brand-name drugs, as well as upcoming generic drug approvals.

Brand and Generic Drugs

Member Free

Non-Member $30.00

Budget Impact Models: How Payers Can Build and Validate - Nexus 2017

Contact Hours: 1.5. Budget impact models (BIMs) can be built and used by payers for many decisions, including changes to the formulary.

Hospital/Health Systems

Member Free

Non-Member $30.00

Cannabis Use in Health Care: What Payers Need to Know Home Study

Contact Hours: 1. 0 - Despite a lack of regulatory and legal clarity, significant numbers of patients in Medicare, Medicaid, CHIP, and commercial plans currently use medical cannabis.

AMCP eLearning Days Cannabis

Member $15.00

Non-Member $30.00

Checking In on Health Care Reform Efforts: What Do They Mean for Payers, Manufacturers and Patients?

Contact Hours: 1.5. While broader drug pricing reform efforts have taken the lion’s share of attention in health policy discourse over the past year, the Trump Administration has continued to move forward with implementing changes to the Affordable Care Act (ACA).

Health Care Reform

Member Free

Non-Member $30.00

Collaborative Multiple Sclerosis Care Management Approach

Contact Hours: 1.5. Multiple sclerosis is a debilitating, chronic illness and a key driver of medical and pharmacy costs.

Multiple Sclerosis

Member Free

Non-Member $30.00

Coverage and Reimbursement for High Cost Curative Therapeutics: Does a Solution Exist? - Nexus 2018

Contact Hours: 1.5. More and more, managed care organizations are straddling the line between making new, innovative therapies available to their patients and ensuring they can cover the costs of these therapies.

Drug Pricing

Member Free

Non-Member $30.00

Developing Professional Strategies to Enhance Digital Engagement

Not Accredited for CPE: 2020 will no doubt be the year of digital engagement. On this webinar, Digital Marketing Strategist Eddie Bradley will share tips and insights on how subject matter experts and industry leading brands are leveraging content to grow and further engage with their audience.

Digital Engagement AMCP eLearning Days

Member $15.00

Non-Member $30.00

Developments, Research, Pipeline, and Applications of Gene Therapy - Annual 2019

Contact Hours: 0.75: Gene therapy is a promising treatment option for a number of diseases, including inherited disorders, some types of cancer, and certain viral infections. The first gene therapy approvals in the United States occurred in 2017.

Gene Therapy

Member Free

Non-Member $30.00

Diabetes: Value Based Insurance Designs (VBID) Real World Evidence

Contact Hours: 1.5. Self-insured employers frequently consider implementing a diabetes value-based insurance design (VBID) as a cost-effective solution for their employees.

Diabetes

Member Free

Non-Member $30.00

Digital Therapeutics: Understanding the Emerging Product Class Home Study

Contact Hours: 1.0. Digital therapeutics (DTx) are emerging as a novel treatment modality for a wide range of health conditions, either as stand-alone products or for use in conjunction with other treatments.

Digital Health AMCP eLearning Days

Member Free

Non-Member $30.00

Drug Pipeline: Traditional Pharmaceuticals and Biosimilars Home Study

Contact Hours: 1.0. This session focuses on new and emerging traditional pharmaceutical brand-name drugs, as well as upcoming generic and biosimilar drug approvals.

Drug Pipeline AMCP eLearning Days

Member Free

Non-Member $30.00

End of an Era: Lessons Learned from 2018 CMS Audits, and Prep for the Future - Nexus 2018

Contact Hours: 1.5. Ready for that upcoming 2019 audit? Do you know how to prepare? If your answer is no, join this session to hear how health plans prepare for their audits and address corrective actions, as lessons learned from the 2018 audit season are discussed.

CMS

Member Free

Non-Member $30.00

Evaluating Digital Therapeutics, Drugs, and Health Technology for Optimizing Clinical and Financial Outcomes Home Study

Contact Hours: 1.0. Utilization management practices are applied to medications in many therapeutic areas, but present unique challenges with digital therapeutics (DTx) and digital health tools.

Digital Health AMCP eLearning Days

Member Free

Non-Member Free

Expanding the Managed Care Professional’s Digital Therapeutics IQ - Home Study

Contact Hours: 1.5. Digital therapeutics are expanding the boundaries of the types of therapies that health care decision-makers must be adept at evaluating.

Digital Health

Member Free

Non-Member $30.00

Experience and Lessons Learned in Biosimilar Uptake - Nexus 2018

Contact Hours: 1.5. Although biosimilars have been on the market for some time, payers continue to face many challenges in implementation.

Biosimilars

Member $15.00

Non-Member $30.00

Fast and Furious: What is Driving the Specialty Spend?

Contact Hours: 1.5. In 2018, the United States spent an estimated $517 million on specialty drugs. While specialty medications make up only about 1–2 % of all prescriptions written, they account for nearly 50% of total drug spend.

Specialty Drug Spend

Main Catalog

Error